Piperacillin-Tazobactam Adverse Event Analysis from FAERS and Clinical Cases

Jing Lu's dataset integrates clinical case observations with a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) to characterize piperacillin-tazobactam-associated thrombocytopenia and anemia. The analysis includes results from four quantitative methods: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS). The dataset was last updated on 2026-05-21 and is licensed under CC-BY-4.0.

Use Cases

• Validate drug safety signals for thrombocytopenia based on disproportionality analysis scores (ROR, PRR, BCPNN, MGPS).
• Correlate large-scale pharmacovigilance data with detailed clinical case series of hematological toxicity.
• Assess the relative strength of adverse event signals for anemia versus thrombocytopenia associated with a specific antibiotic.
• Support clinical monitoring recommendations by analyzing the timing and severity of adverse reactions mentioned in the case series.

Strengths

• Analysis is based on the FDA Adverse Event Reporting System (FAERS), a large-scale pharmacovigilance database.
• Employs four established disproportionality analysis methods (ROR, PRR, BCPNN, MGPS) for signal detection.
• Includes specific quantitative results, such as an ROR of 5.26 (95% CI 4.81–5.74) for thrombocytopenia.
• Combines statistical analysis with detailed clinical case observations for contextual evidence.

Limitations

• Dataset is very small (22.7 KB), indicating limited raw data or summary-level results only.
• Row count and column-level documentation are unknown; data structure must be inferred after download.
• The clinical case series component is likely based on a very small sample (three patients).

Provenance

Source

FDA Adverse Event Reporting System (FAERS) and author's clinical case series.

Collection Method

Disproportionality analysis and clinical case review.

Freshness

Last updated 2026-05-21 05:33:55.